日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Implementation of values-based healthcare in inflammatory bowel disease-a review

在炎症性肠病中实施基于价值的医疗保健——一项综述

Hilley, Patrick; Chin, Simone; Wong, Darren; De Cruz, Peter

Diagnostic Accuracy of Noninvasive Biomarkers and Imaging for Evaluating Postoperative Recurrence in Crohn's Disease

无创生物标志物和影像学在评估克罗恩病术后复发中的诊断准确性

Samnani, Sunil; Ray, Christina M; Gill, Priyanka; Stein, Levi; Buhler, Katherine A; Leong, Rupert W; Smith, Rebecca L; De Cruz, Peter; Kaplan, Gilaad G; Seow, Cynthia H; Lu, Cathy; Guizzetti, Leonardo; Hoentjen, Frank; Marshall, John K; Singh, Siddharth; Panaccione, Remo; Novak, Kerri L; Ma, Christopher

Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints

急性重症溃疡性结肠炎:临床试验设计和终点的国际德尔菲共识

Honap, Sailish; Jairath, Vipul; Sands, Bruce E; Dulai, Parambir S; Higgins, Peter D R; De Cruz, Peter; Gutiérrez, Ana; Kotze, Paulo G; Ye, Byong Duk; Kobayashi, Taku; Gearry, Richard B; Olivera, Pablo A; Amiot, Aurélien; Mosli, Mahmoud H; Al Awadhi, Sameer; Halfvarson, Jonas; Patel, Kamal V; Sebastian, Shaji; Danese, Silvio; Peyrin-Biroulet, Laurent

Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation

在接受肝移植的炎症性肠病患者中,全身生物制剂与维多珠单抗具有相似的安全性。

Chin, Simone; Con, Danny; Hilley, Patrick; Corte, Crispin; Liu, Ken; Testro, Adam; De Cruz, Peter; Choy, Matthew C; Srinivasan, Ashish

IBD 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, Australia

IBD 2024:IBD 新航向——武田研讨会论文集,2024 年 11 月 22-23 日,澳大利亚昆士兰州布里斯班 W 酒店

Mahadevan, Uma; Jairath, Vipul; Begun, Jakob; Pudipeddi, Aviv; Garg, Mayur; De Cruz, Peter; Li Wai Suen, Christopher F D; Choy, Matthew C; Con, Danny; Vaughan, Rose; Chetwood, John D; Clark, David A; Haifer, Craig; Sparrow, Miles P; Leong, Rupert; Mountifield, Réme

Australian Real-World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the AURORA Study, Including the ANZIBD Consortium

澳大利亚乌司奴单抗治疗克罗恩病的真实世界疗效和安全性:AURORA 研究结果,包括 ANZIBD 联盟

An, Yoon-Kyo; Lindsay, Niamh; Allan, Natalie; Khoo, Emi; Fernandes, Richard; Gilmore, Robert; Amiss, Anna; Pham, Hai; Ooi, Soong-Yuan; Thin, Lena; Lightowler, Daniel; Connor, Susan J; Williams, Astrid; De Cruz, Peter; Li Wai Suen, Christopher F D; Kariyawasam, Viraj; Mitrev, Nikola; Ghaly, Simon; Andrews, Jane M; Christensen, Britt; Sparrow, Miles P; White, Lauren S; Bryant, Robert; Ding, Nik S; Leong, Rupert W; Van Langenberg, Daniel R; Seltenreich, Hansjoerg; Subramaniam, Kavitha; Radford-Smith, Graham; Begun, Jakob

Tofacitinib in Stricturing Colonic Crohn's Disease

托法替尼治疗狭窄型结肠克罗恩病

Chin, Simone; Choy, Matthew; De Cruz, Peter

BECLIN-1 is essential for the maintenance of gastrointestinal epithelial integrity by regulating endocytic trafficking, F-actin organization, and lysosomal function.

BECLIN-1 通过调节内吞运输、F-肌动蛋白组织和溶酶体功能,对维持胃肠道上皮完整性至关重要

Juliani Juliani, Tran Sharon, Harris Tiffany J, De Cruz Peter, Ellis Sarah L, Gleeson Paul A, Mariadason John M, Duszyc Kinga, Yap Alpha S, Lee Erinna F, Fairlie Walter D

Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study

治疗目标应影响炎症性肠病中英夫利昔单抗剂量强化策略的选择:一项药代动力学模拟研究

Srinivasan, Ashish; van Langenberg, Daniel; De Cruz, Peter; Segal, Jonathan; Vasudevan, Abhinav; Upton, Richard N

Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis

生物制剂治疗伴有炎症性肠病的原发性硬化性胆管炎的疗效和安全性:系统评价和荟萃分析

Shah, Ayesha; Jones, Michael P; Callaghan, Gavin; Fairlie, Thomas; Ma, Xiaomin; Culver, Emma L; Stuart, Katherine; De Cruz, Peter; O'Beirne, James; Tabibian, James H; Dignass, Axel; Canbay, Ali; Gores, Gregory J; Holtmann, Gerald J